1. Introduction {#sec1}
===============

Glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate \[[@bib1]\]. It is located in the endoplasmic reticulum (ER) membrane and exists as a multi-component enzyme system in which a G6P transporter, encoded by the *SLC37A4* gene, delivers substrate from the cytosol to the active site of a glucose-6-phosphatase catalytic subunit (G6PC) in the lumen of the ER, with transporters for inorganic phosphate and glucose returning the reaction products back to the cytosol \[[@bib1]\]. The *G6PC* gene family is comprised of three members, namely *G6PC1*, *G6PC2* and *G6PC3* \[[@bib1]\]. *G6PC1* is predominantly expressed in liver and kidney where it catalyzes the terminal step in the gluconeogenic and glycogenolytic pathways, whereas *G6PC3* is widely expressed, with especially high expression in kidney, testis, skeletal muscle and brain \[[@bib1]\]. Based on Northern blotting, immunohistochemistry and RNA-Seq data, *G6PC2*, also known as *IGRP*, is predominantly expressed in pancreatic islets. In mice, *G6pc2* is expressed at ∼20 fold higher levels in pancreatic islet beta cells than alpha cells whereas in humans *G6PC2* is expressed at a ∼5 fold higher level in beta than alpha cells \[[@bib2], [@bib3], [@bib4]\].

G6PC2 acts in conjunction with the beta cell glucose sensor, glucokinase, to create a futile substrate cycle that determines the rate of beta cell glycolytic flux \[[@bib5], [@bib6], [@bib7]\]. In turn, this futile cycle determines the sensitivity of glucose-stimulated insulin secretion (GSIS) to glucose, and hence the influence of beta cells on fasting blood glucose (FBG) \[[@bib5],[@bib6]\]. Key evidence in support of this model are the observations that, in isolated *G6pc2* knockout (KO) islets, glucose-6-phosphatase activity \[[@bib7]\] and glucose cycling \[[@bib8]\], calculated as the percentage of the G6P generated from glucose that is converted back to glucose, are both reduced. This results in a leftward shift in the dose response curve for GSIS \[[@bib7]\] such that under fasting conditions, insulin levels are the same in wild type (WT) and *G6pc2* KO mice but FBG is reduced in KO mice \[[@bib7],[@bib9]\]. This same shift in glucose sensitivity results in increased insulin secretion from isolated *G6pc2* KO islets in response to sub-maximal glucose \[[@bib7]\]. The same results are observed in both germline \[[@bib7]\] and beta cell-specific \[[@bib10]\] *G6pc2* KO mice, consistent with the predominant expression of *G6pc2* in beta cells and suggesting that trace *G6pc2* expression in peripheral tissues is not biologically important. This model is also consistent with genome-wide association and molecular studies that have linked the rs560887 'A' allele to reduced *G6PC2* expression and reduced FBG \[[@bib11], [@bib12], [@bib13]\].

A key question is the nature of the physiological benefit conferred by this glucokinase/G6PC2 substrate cycle. Experiments in mice in which glucocorticoids were injected or endogenous glucocorticoids were elevated by physical restraint induced *G6pc2* expression \[[@bib14],[@bib15]\]. The associated change in FBG in KO relative to WT mice suggests that G6PC2 may have evolved, in part, to confer a transient, beneficial elevation in FBG during periods of stress \[[@bib14],[@bib15]\]. The experiments described here extend these studies by examining the role of G6PC2 in the response to different nutritional challenges and suggest that G6PC2 evolved to not only regulate FBG in response to stress, but also to prevent hypoglycemia associated with prolonged fasting and ketogenic diets.

2. Materials and methods {#sec2}
========================

2.1. Animal care {#sec2.1}
----------------

The Vanderbilt University Medical Center Animal Care and Use Committee approved all protocols used. Mice were maintained on either a standard rodent chow diet (LabDiet 5001, PMI Nutrition International, which comprises 24% protein; 5% fat \[linoleic acid, 1.16%; linolenic acid, 0.07%; total saturated fatty acids, 1.50%; total monounsaturated fatty acids, 1.58%\]) and 49% carbohydrate (starch, 31.9%; glucose, 0.22%; fructose 0.3%; sucrose, 3.7%; lactose 2.0%) with calories from protein (29%), fat (13%) and carbohydrate (58%)) or a high fat diet (Mouse Diet F3282; BioServ, which comprises 21% protein; 36% fat \[linoleic acid, 3.7%; linolenic acid, 0.4%; total saturated fatty acids, 14.1%; total monounsaturated fatty acids, 16.2%\]) and 37% carbohydrate (monosaccharides, 0.1%; disaccharides, 14.6%; polysaccharides, 20%) with calories from protein (15%), fat (59%) and carbohydrate (26%) or a ketogenic diet (Mouse Diet F3666; BioServ, which comprises 8.6% protein; 75.1% fat \[linoleic acid, 11.5%; linolenic acid, 0.7%; total saturated fatty acids, 30.3%; total monounsaturated fatty acids, 28.8%\]) and 3.2% carbohydrate (monosaccharides, 0.7%; disaccharides, 2.5%; polysaccharides, 0%) with calories from protein (5%), fat (93%) and carbohydrate (2%) as indicated. Mice were placed on the diet at 8 weeks of age for 1--8 weeks for ketogenic diet studies, whereas for high fat diet studies, mice were placed on the diet at 33 weeks of age for 10--13 weeks. Food and water were provided *ad libitum*.

2.2. Generation of germline *G6pc2* KO mice {#sec2.2}
-------------------------------------------

The generation of germline *G6pc2* KO mice on a pure C57BL/6J genetic background has been previously described \[[@bib7],[@bib9]\].

2.3. *In vivo* phenotypic analyses {#sec2.3}
----------------------------------

Intraperitoneal glucose tolerance tests (IPGTTs), insulin tolerance tests (ITTs), plasma cholesterol and blood glucose, were all measured in 6-hr fasted mice as previously described \[[@bib7],[@bib16],[@bib17]\]. Plasma ketones were measured using the Ketone Body Assay Kit (Sigma). Plasma insulin and glucagon were assayed by the Vanderbilt Hormone Assay and Analytical Services Core using RIA or a highly specific and sensitive immunoassay (Mercodia; Kit \#10-1271-01), respectively.

2.4. Analysis of gene expression {#sec2.4}
--------------------------------

Pancreatic and liver RNA were isolated using the ToTALLY RNA kit (Ambion, Carlsbad, CA). The Turbo DNA-free DNAse Treatment Kit (Ambion, Carlsbad, CA) was then used to remove trace genomic DNA followed by cDNA generation using the iScript DNA Synthesis Kit (Bio-Rad, Hercules, CA). Gene expression was then quantitated by PCR using the dUTP-containing FastStart SYBR Green Master Mix in conjunction with Uracil-DNA-Glycosylase (Roche, Nutley, NJ). Fold induction of gene expression was calculated using the 2 (-ΔΔC(T)) method \[[@bib18]\]. PCR primer sequences have been previously described \[[@bib10]\]. The efficiency of primer amplification was tested in cDNA dilution analyses. These showed that correlation coefficients were ∼0.99 and PCR efficiency was ∼95%.

2.5. Mouse islet isolation and glucose cycling {#sec2.5}
----------------------------------------------

Mouse islets were isolated by the Vanderbilt Islet Procurement and Analysis Core and glucose cycling was measured as previously described \[[@bib8]\].

2.6. Statistical analyses {#sec2.6}
-------------------------

Mouse data were analyzed using a Student\'s t-test, two-sample assuming equal variance or a one-way ANOVA, assuming normal distribution and equal variance, as indicated. *Post hoc* analyses were performed using the Bonferroni correction for multiple comparisons. The level of significance was as indicated.

3. Results {#sec3}
==========

3.1. G6PC2 confers protection against hypoglycemia upon ketogenic diet feeding {#sec3.1}
------------------------------------------------------------------------------

To understand why the *G6PC2* gene would have been conserved across multiple species over the course of evolution, we considered the benefits that a glucokinase/G6PC2 futile substrate cycle might confer under different dietary conditions. We hypothesized that when carbohydrate-rich foods were scarce, G6PC2 might have been beneficial by limiting basal GSIS and therefore conferring protection against hypoglycemia. We investigated the response of WT and *G6pc2* KO mice to ketogenic diet feeding to address that hypothesis.

Significant weight loss was observed in WT and *G6pc2* KO mice one day after switching mice from a chow diet to a ketogenic diet ([Figure 1](#fig1){ref-type="fig"}A) and this was associated with a marked decrease in both fasting blood glucose (FBG) ([Figure 1](#fig1){ref-type="fig"}B) and fasting plasma insulin (FPI) ([Figure 1](#fig1){ref-type="fig"}C), with KO mice becoming hypoglycemic (64−/+2 mg/dl glucose). Glucagon levels were significantly elevated in KO mice after 1 day on the ketogenic diet relative to WT mice, but this increase was insufficient to prevent hypoglycemia ([Figure 1](#fig1){ref-type="fig"}D). These data suggest that G6PC2 confers protection against hypoglycemia upon ketogenic diet feeding.Figure 1**Analysis of Metabolic Parameters in Male WT and *G6pc2* KO Mice on a Ketogenic Diet.** Body weight (Panel **A**), FBG (Panel **B**), FPI (Panel **C**) and plasma glucagon (Panel **D**) were compared in 6-hr fasted WT (W) and KO (K) mice before, and/or 1 day after, switching from a chow diet to ketogenic diet at 8 weeks of age. ∗p \< 0.05 WT vs KO; \#p \< 0.05 WT at day 0 vs WT at day 1 of ketogenic diet feeding; ˆp \< 0.05 KO at day 0 vs KO at day 1 of ketogenic diet feeding. Body weight (Panel **E**), plasma ketones (beta-hydroxybutyric acid; BHBA) (Panel **F**), FPI (Panel **G**) and FBG (Panel **H**) were compared in non-fasted (Panel **E**) or 6-hr fasted (Panels **F--H**) WT and KO mice that were switched from a chow diet to a ketogenic diet at 8 weeks of age. ∗p \< 0.05 WT vs KO; \#p \< 0.05 WT at day 0 vs WT after ketogenic diet feeding; ˆp \< 0.05 KO at day 0 vs KO after ketogenic diet feeding; ∗∗p \< 0.05 KO at day 7 vs KO at day 28 of ketogenic diet feeding. Results show the mean data ± S.E.M. with the genotype and number of animals analyzed indicated. Statistical significance was analyzed using ANOVA (Panels **A**--**E**, **G** & **H**) or t-tests (Panel **F**).Figure 1

We next investigated the response to prolonged ketogenic diet feeding. [Figure 1](#fig1){ref-type="fig"}E shows that the weight loss observed in both WT and *G6pc2* KO mice upon switching from a chow diet to a ketogenic diet is transient. Both WT and *G6pc2* KO mice returned to their initial starting weight after 21 days on the ketogenic diet ([Figure 1](#fig1){ref-type="fig"}E). After 35 days on the ketogenic diet, WT mice gained additional weight and exceeded their initial starting weight, whereas KO mice remained at their initial starting weight even after 56 days on the diet, resulting in a significant difference in body weight between WT and *G6pc2* KO mice ([Figure 1](#fig1){ref-type="fig"}E). Ketone levels were significantly elevated in both WT and KO mice after 56 days on the ketogenic diet ([Figure 1](#fig1){ref-type="fig"}F).

FPI ([Figure 1](#fig1){ref-type="fig"}G) and FBG ([Figure 1](#fig1){ref-type="fig"}H) were significantly lower in both WT and *G6pc2* KO mice after 7 days of ketogenic diet feeding and remained lower after 56 days. FPI did not differ between WT and *G6pc2* KO mice at any time ([Figure 1](#fig1){ref-type="fig"}G). However, the fall in FBG observed in *G6pc2* KO mice after 1 ([Figure 1](#fig1){ref-type="fig"}A) and 7 ([Figure 1](#fig1){ref-type="fig"}H) days of ketogenic diet feeding was partially reversed between 7 and 28 days of ketogenic diet feeding ([Figure 1](#fig1){ref-type="fig"}H). While a significant difference in FBG was observed in chow-fed WT and *G6pc2* KO mice ([Figure 1](#fig1){ref-type="fig"}H; day 0) and after 1 ([Figure 1](#fig1){ref-type="fig"}A) and 7 ([Figure 1](#fig1){ref-type="fig"}H) days of ketogenic diet feeding, this difference between WT and KO mice was lost after 28 days on the ketogenic diet ([Figure 1](#fig1){ref-type="fig"}H).

Additional studies were then performed to determine why prolonged ketogenic diet feeding appears to abolish the influence of G6PC2 on FBG. Similar to chow-fed mice \[[@bib7]\], WT and *G6pc2* KO mice on a ketogenic diet showed no differences in insulin sensitivity ([Figure 2](#fig2){ref-type="fig"}A) or glucose tolerance following intraperitoneal injection of 2 g/kg glucose ([Figure 2](#fig2){ref-type="fig"}B), and the rise in blood glucose following intraperitoneal glucose injection in WT and KO mice ([Figure 2](#fig2){ref-type="fig"}C) was not associated with a difference in the rise in plasma insulin ([Figure 2](#fig2){ref-type="fig"}D).Figure 2**Analysis of Metabolic Parameters, Glucose Cycling and Gene Expression in Male WT and *G6pc2* KO Mice on a Ketogenic Diet.** Insulin sensitivity (Panel **A**), intraperitoneal (IP) glucose tolerance (Panel **B**) and both blood glucose (Panel **C**) and plasma insulin (Panel **D**) before and after IP glucose injection (2 g/kg) were compared in 6-hr fasted 16--18 week old WT and KO mice after 8--10 weeks of ketogenic diet feeding. \#p \< 0.05 WT at t = 0 vs WT at t = 15; ˆp \< 0.05 KO at t = 0 vs KO at t = 15. Comparison of pancreatic expression of genes known to be highly expressed in islets (Panel **E**) in 6-hr fasted 16 week old chow-fed (C) WT mice versus 6-hr fasted 16 week old WT mice that were switched to a ketogenic diet (KG) at 8 weeks of age. Data were corrected relative to *Ppia* (cyclophilin A) expression. ∗p \< 0.05 chow vs ketogenic diet. Comparison of glucose uptake (Panel **F**) and glucose cycling (Panel **G**) rates at 11 mM glucose in islets isolated from 16 week old WT (W) and KO (K) mice that were switched to a ketogenic diet at 8 weeks of age. ∗p \< 0.05 WT vs KO. Intraperitoneal glucose tolerance (Panel **H**) after IP glucose injection (0.75 g/kg) was analyzed in 6-hr fasted 16--18 week old WT and KO mice after 8--10 weeks of ketogenic diet feeding. Results show the mean data ± S.E.M. with the genotype and number of animal/islet preparations analyzed indicated. Statistical significance was analyzed using ANOVA (Panels **A**--**D, H**) or t-tests (Panels **E-G**).Figure 2

To assess whether ketogenic diet feeding affected expression of *G6pc2*, we specifically analyzed *G6pc2* gene expression in addition to other genes known to be highly expressed in islets but not acinar cells, in whole pancreas RNA preparations. This approach captures expression levels in the *in vivo* islet environment and avoids the confounding issue of gene expression changing during islet isolation. The switch from a chow to ketogenic diet was associated with a significant but modest induction of *G6pc2* and *Slc2a2* with no change in *Ins2* or *Slc30a8* gene expression ([Figure 2](#fig2){ref-type="fig"}E). The absence of a marked change in *G6pc2* expression is consistent with the observation that the rate of glucose uptake ([Figure 2](#fig2){ref-type="fig"}F) and glucose cycling ([Figure 2](#fig2){ref-type="fig"}G) in islets isolated from mice on a ketogenic diet is similar to that in islets isolated from mice on a chow diet \[[@bib8]\], with the deletion of *G6pc2* abolishing glucose cycling as expected ([Figure 2](#fig2){ref-type="fig"}G). The small induction of *G6pc2* expression would be predicted to protect against hypoglycemia but was surprising because glucose has a marked stimulatory effect on *G6pc2* gene expression \[[@bib19]\]. We therefore expected that the fall in FBG associated with ketogenic diet feeding would lead to a reduction in *G6pc2* expression. Similarly, because *Slc2a2* gene expression is also stimulated by glucose \[[@bib20]\], we expected to observe a decrease rather than increase in expression ([Figure 2](#fig2){ref-type="fig"}E). These observations suggest that other unknown factors associated with ketogenic diet feeding modulate the expected effect of glucose on *G6pc2* and *Slc2a2* expression.

While these observations provide no explanation as to why prolonged ketogenic diet feeding abolishes the influence of G6PC2 on FBG, glucose tolerance tests using a lower intraperitoneal injection of 0.75 g/kg glucose showed that *G6pc2* deletion was associated with a significant improvement in glucose tolerance ([Figure 2](#fig2){ref-type="fig"}H). This suggests a specific loss of influence of G6PC2 on FBG rather than a complete loss of function.

3.2. G6PC2 confers protection against hypoglycemia upon prolonged fasting {#sec3.2}
-------------------------------------------------------------------------

We next investigated the response of chow-fed WT and *G6pc2* KO mice to prolonged fasting. A 24-hr fast resulted in significant reductions in body weight ([Figure 3](#fig3){ref-type="fig"}A), FBG ([Figure 3](#fig3){ref-type="fig"}B) and FPI ([Figure 3](#fig3){ref-type="fig"}C) relative to 6-hr fasted mice. FPI did not differ between WT and *G6pc2* KO mice ([Figure 3](#fig3){ref-type="fig"}C) whereas the significant difference in FBG observed in 6-hr fasted WT and *G6pc2* KO mice was still apparent after a 24-hr fast ([Figure 3](#fig3){ref-type="fig"}B), with KO mice becoming hypoglycemic (70−/+1 mg/dl glucose). A difference in glucagon levels between WT and KO mice was not observed despite the hypoglycemia in KO mice ([Figure 3](#fig3){ref-type="fig"}D). These data suggest that G6PC2 confers protection against hypoglycemia upon prolonged fasting.Figure 3**Analysis of Metabolic Parameters and Gene Expression in Male WT and *G6pc2* KO Mice After Prolonged Fasting.** Body weight (Panel **A**), FBG (Panel **B**), FPI (Panel **C**) and plasma glucagon (Panel **D**) were compared in 6-hr and/or 24-hr fasted 16 week old male WT (W) and KO (K) mice. ∗p \< 0.05 WT vs KO; \#p \< 0.05 6-hr fasted WT vs 24-hr fasted WT; ˆ p \< 0.05 6-hr fasted KO vs 24-hr fasted KO. Comparison of pancreatic expression of genes known to be highly expressed in islets (Panel **E**) or liver (Panel **G**) in 6-hr versus 24-hr fasted 16 week old male WT mice. Data were corrected relative to *Ppia* (cyclophilin A) expression. ∗p \< 0.05 6-hr fasted WT vs 24-hr fasted WT. Results show the mean data ± S.E.M. with the genotype and number of animals analyzed indicated. Statistical significance was analyzed using ANOVA (Panels **A-C**) or t-tests (Panels **D-F**).Figure 3

Prolonged fasting was associated with a significant ∼50% fall in pancreatic *G6pc2* and *Slc2a2* gene expression with no change in *Ins2* or *Slc30a8* gene expression ([Figure 3](#fig3){ref-type="fig"}E). Unlike the complex effects of ketogenic diet feeding on pancreatic *G6pc2* and *Slc2a2* gene expression ([Figure 2](#fig2){ref-type="fig"}), the fall observed with fasting is consistent with a reduction in the stimulatory effect of glucose on those genes ([Figure 2](#fig2){ref-type="fig"}D) \[[@bib19],[@bib20]\]. Our previous studies on heterozygous *G6pc2* mice have shown an intermediate effect on FBG relative to KO mice \[[@bib7],[@bib9]\], therefore, we would speculate that this decrease in *G6pc2* expression would lower FBG relative to WT, but not sufficiently to result in hypoglycemia and instead would serve to promote enhanced glucose clearance during re-feeding ([Figure 2](#fig2){ref-type="fig"}H). Furthermore, a partial reduction in *G6pc2* expression during fasting would allow blood glucose to fall even more so as to minimize glucose usage while maintaining some insulin to brake proteolysis while keeping free fatty acid availability high.

In contrast to *G6pc2*, which is not expressed in the liver \[[@bib10]\] and is not regulated by insulin (data not shown), hepatic *G6pc1* expression increases significantly with fasting ([Figure 3](#fig3){ref-type="fig"}F). Because insulin represses \[[@bib1]\] whereas glucose stimulates \[[@bib21]\] *G6pc1* expression, this suggests that the effect of reduced repression of *G6pc1* expression by insulin associated with the reduction in FPI ([Figure 3](#fig3){ref-type="fig"}C) is dominant over the effect of reduced stimulation by glucose associated with the reduction in FBG ([Figure 3](#fig3){ref-type="fig"}B).

3.3. G6PC2 limits hyperglycemia upon high fat diet feeding {#sec3.3}
----------------------------------------------------------

While prolonged fasting and ketogenic diets may have been common over the course of evolution, high fat diets are more prevalent in the modern world. We previously showed that 8 week old C57BL/6J *G6pc2* KO male mice were not protected against diet induced obesity (DIO) when switched from a chow diet to a high fat diet and that the magnitude of the difference in FBG between WT and KO mice was not affected by 12 weeks of high fat feeding \[[@bib7]\]. However, recent studies have shown that aging affects the response of islets to high fat feeding \[[@bib22]\], so we reasoned that the outcome may be different in older mice.

Switching 33 week old mice from a chow diet to a high fat diet resulted in significant weight gain in both WT and *G6pc2* KO mice ([Figure 4](#fig4){ref-type="fig"}A) and, as in young mice \[[@bib7]\], no difference in body weight emerged between WT and *G6pc2* KO mice. Plasma cholesterol ([Figure 4](#fig4){ref-type="fig"}B), FPI ([Figure 4](#fig4){ref-type="fig"}C) and FBG ([Figure 4](#fig4){ref-type="fig"}D) were all significantly elevated following high fat diet feeding. The elevation in plasma cholesterol was greater in WT than KO mice after 84 days on the diet ([Figure 4](#fig4){ref-type="fig"}B), as previously reported \[[@bib23]\]. The elevation in FBG in WT and KO mice was apparent after 28 days of high fat diet feeding and the significant difference in FBG between WT and *G6pc2* KO mice remained after 84 days ([Figure 4](#fig4){ref-type="fig"}D). As concluded from studies in young mice \[[@bib7]\], these data again suggest that inhibition of G6PC2 would limit but not prevent the hyperglycemia associated with high fat diet feeding.Figure 4**Analysis of Metabolic Parameters and Gene Expression in Male WT and *G6pc2* KO Mice on a High Fat Diet.** Body weight (Panel **A**), plasma cholesterol (Panel **B**), FPI (Panel **C**) and FBG (Panel **D**) were compared in non-fasted (Panel **A**) or 6-hr fasted (Panels **B-D**) WT and KO mice that were switched from a chow diet to a high fat (HF) diet at 33 weeks of age. ∗p \< 0.05 WT vs KO; \#p \< 0.05 WT at day 0 vs WT after high fat diet feeding; ˆp \< 0.05 KO at day 0 vs KO after high fat diet feeding. Comparison of pancreatic expression of genes known to be highly expressed in islets (Panel **E**) in 6-hr fasted 33 week old chow fed WT mice versus 6-hr fasted 45 week old WT mice that were switched to a high fat diet at 33 weeks of age. Data were corrected relative to *Ppia* (cyclophilin A) expression. ∗p \< 0.05 chow vs high fat fed (HF). FBG (Panel **F**) in 45 week old male WT and KO mice that were placed on a high fat diet at 33 weeks of age after a 6-hr or 18-hr fast. ∗p \< 0.05 WT vs KO; \#p \< 0.05 6-hr fasted WT vs 18-hr fasted WT; ˆp \< 0.05 6-hr fasted KO vs 18-hr fasted KO. Comparison of pancreatic expression of genes known to be highly expressed in islets in 45 week old 6-hr fasted male WT mice that were placed on a high fat diet at 33 weeks of age versus 24 week old 18-hr fasted male WT mice that had been placed on a high fat diet at 12 weeks of age (Panel **G**). ∗p \< 0.05 6-hr fasted WT vs 18-hr fasted WT. Comparison of hepatic *G6pc1* expression in 6-hr fasted 33 week old chow-fed WT mice versus 6-hr fasted 45 week old WT mice that were switched to a high fat diet at 33 weeks of age (Panel **H**). Data were corrected relative to *Ppia* (cyclophilin A) expression. ∗p \< 0.05 chow vs high fat fed (HFF). Results show the mean data ± S.E.M. with the genotype and number of animals indicated. Statistical significance was analyzed using ANOVA (Panels **A-D, F**) or t-tests (Panels **E, G & H**).Figure 4

The switch from a chow diet to a high fat diet was associated with marked changes in pancreatic *G6pc2* as well as *Ins2*, *Slc2a2* and *Slc30a8* gene expression ([Figure 4](#fig4){ref-type="fig"}E) that are highly likely to be due in part to the well-characterized effects of high fat diet feeding on pancreatic islet mass \[[@bib24]\]. After 18-hr fasting, the FBG levels in previously high fat fed mice ([Figure 4](#fig4){ref-type="fig"}F) were similar to those in 6-hr fasted chow fed mice ([Figure 1](#fig1){ref-type="fig"}B). Prolonged fasting was associated with a significant ∼50% fall in pancreatic *G6pc2* gene expression with no change in *Ins2*, *Slc2a2* or *Slc30a8* gene expression ([Figure 4](#fig4){ref-type="fig"}G). This fall in *G6pc2* expression in previously high fat fed mice after prolonged fasting mimics that in mice that were previously fed a chow diet ([Figure 3](#fig3){ref-type="fig"}E) and is consistent with a reduction in the stimulatory effect of glucose \[[@bib19]\]. It is unclear why a similar decrease in *Slc2a2* expression is not observed in response to reduced FBG.

In contrast to the marked induction of *G6pc2* expression by high fat feeding ([Figure 4](#fig4){ref-type="fig"}E), hepatic *G6pc1* expression was significantly decreased ([Figure 4](#fig4){ref-type="fig"}H). Because insulin represses \[[@bib1]\] whereas glucose stimulates \[[@bib21]\] *G6pc1* expression, this suggests that the effect of increased repression by insulin associated with the elevated FPI ([Figure 4](#fig4){ref-type="fig"}C) is dominant over the effect of increased stimulation by glucose associated with the elevated FBG ([Figure 4](#fig4){ref-type="fig"}D).

4. Discussion {#sec4}
=============

The experiments described here suggest that G6PC2 may have evolved to not only confer a beneficial elevation in FBG in response to stress \[[@bib14],[@bib15]\] but also to prevent hypoglycemia in response to ketogenic diet feeding ([Figure 1](#fig1){ref-type="fig"}) or prolonged fasting ([Figure 3](#fig3){ref-type="fig"}). In contrast, in response to high fat diet feeding, as is common in the modern world, the presence of G6PC2 amplifies the hyperglycemia ([Figure 4](#fig4){ref-type="fig"}).

Elevated FBG and HbA(1C) levels in humans have been associated with an increased risk for the development of cardiovascular-associated mortality (CAM) \[[@bib25], [@bib26], [@bib27]\]. This correlation with CAM is observed in both women and men \[[@bib27]\] and even at glucose concentrations in the non-diabetic range, although the risk of CAM increases still further in individuals with the high FBG levels characteristic of diabetes \[[@bib25], [@bib26], [@bib27], [@bib28]\]. Even small differences in FBG have a profound effect over time. For example, a reduction in FBG from 99 to 90 mg/dl in Asians is associated with a 25% reduction in the risk of CAM \[[@bib27]\] and in Europeans an increase in FBG levels from less than 90 mg/dl to between 99 and 108 mg/dl is associated with a 30% increased risk of CAM \[[@bib25]\]. Similarly, studies in pregnant women have shown continuous associations of maternal glucose levels below those diagnostic of diabetes with increased birth weight and increased cord-blood serum C-peptide levels \[[@bib29]\]. Because deletion of *G6pc2* is associated with a ∼20 mg/dl reduction in FBG \[[@bib7],[@bib9],[@bib15]\] the magnitude of this effect, relative to the human data described above, suggests that inhibition of G6PC2 should already be considered as a novel therapeutic strategy for lowering FBG and hence preventing CAM. However, the potential risk of hypoglycemia under specific conditions ([Figure 1](#fig1){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}) suggests that achieving partial inhibition may be the optimal approach.

We have previously observed increased insulin secretion in isolated islets from *G6pc2* KO mice and in perfused KO pancreas in response to a challenge with sub-maximal glucose \[[@bib7]\]. These observations are consistent with a model in which G6PC2 regulates glucose cycling \[[@bib8]\], such that deletion of *G6pc2* shifts the dose response curve for GSIS to the left \[[@bib7]\]. We also see improvements in intraperitoneal glucose tolerance in both *G6pc2* KO mice on a ketogenic diet when injected with submaximal 0.75 g/kg glucose ([Figure 2](#fig2){ref-type="fig"}H) and KO mice on a chow diet when injected with 0.4 g/kg glucose \[[@bib7]\]. Based on these observations one would expect to see increased insulin secretion in KO mice in response to injection with submaximal glucose (0.4--0.75 g/kg) that would then explain the improvement in glucose tolerance. Surprisingly, we have seen no evidence for such an increase in chow-fed mice \[[@bib7]\] and have not attempted this experiment in mice on a prolonged ketogenic diet because even the induction in plasma insulin following a 2 g/kg glucose injection is small and variable ([Figure 2](#fig2){ref-type="fig"}D). We hypothesize that the molecular mechanism for the improved glucose tolerance in the absence of enhanced insulin secretion might relate to an action of G6PC2 on insulin pulsatility, with *G6pc2* deletion enhancing pulsatility and therefore improving glucose tolerance without a requirement for elevated insulin secretion. This concept was suggested by Watanabe and colleagues \[[@bib30]\] based on human genetic data showing that reduced *G6PC2* expression was associated with reduced FBG but also surprisingly reduced, rather than elevated, insulin levels in an oral glucose tolerance test. Future studies will directly address this hypothesis in *G6pc2* KO mice.

We hypothesized that *G6pc2* would be induced by fasting and ketogenic diet feeding to protect against hypoglycemia, however, *G6pc2* expression was surprisingly reduced in response to fasting ([Figure 3](#fig3){ref-type="fig"}) and little changed in response to ketogenic diet feeding ([Figure 2](#fig2){ref-type="fig"}). In contrast, *G6pc2* expression was markedly induced in response to high fat diet feeding ([Figure 4](#fig4){ref-type="fig"}). Because glucose stimulates *G6pc2* expression in isolated islets ([Figure 2](#fig2){ref-type="fig"}), this could explain why *G6pc2* expression is elevated in response to the hyperglycemia associated with high fat diet feeding ([Figure 4](#fig4){ref-type="fig"}) and reduced in response to the hypoglycemia associated with fasting ([Figure 3](#fig3){ref-type="fig"}). However, other factors must regulate *G6pc2* expression because expression did not fall in response to the hypoglycemia associated with ketogenic diet feeding ([Figure 2](#fig2){ref-type="fig"}). Future experiments will explore the nature of these other regulatory factors and also whether the regulation by glucose occurs at a transcriptional or post-transcriptional level. The transcription factors ChREBP and CREB have been shown to be important for mediating the stimulatory effects on glucose on *G6PC1*, but whether these factors are also important for the regulation of *G6PC2* expression is unknown. Future studies that include an examination of G6PC2 protein levels will also seek to understand why the marked induction of *G6pc2* expression in mice on a high fat diet ([Figure 4](#fig4){ref-type="fig"}E) has little effect on the difference in FBG between WT and KO mice ([Figure 4](#fig4){ref-type="fig"}D).
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